Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroectodermal Tumors, Primitive × pegfilgrastim × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1

Interventions

Everolimus 2 trifluridine tipiracil drug combination 1 pegfilgrastim 1 gallium Ga 68 dotatate 1 fosbretabulin 1 dactolisib 1 Temozolomide 1 TH 302 1 Sunitinib 1 Nivolumab 1 Filgrastim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡